Literature DB >> 16025390

The 5-HT hypothesis of schizophrenia.

S Akhondzadeh1.   

Abstract

Schizophrenia is a serious psychiatric illness that is responsible for a substantial proportion of mental illness worldwide. Symptoms include hallucination, delusions, thought disorder and negative symptoms, including poverty of thought and emotion, and social withdrawal. Early theories of schizophrenia implicated disturbed serotonin (5-HT) neurotransmission, but these were largely overshadowed by the dopamine theory of schizophrenia, which became established after the introduction of chlorpromazine. However, the importance of 5-HT in CNS function is once again being recognized. The ability of antipsychotic drugs to diminish positive symptoms has been correlated with their ability to block dopamine D(2) receptors, although negative symptoms are not as effectively treated by typical neuroleptics. There is increasing interest in the correlation between negative symptoms of schizophrenia and 5-HT(2) receptors. The rationale for these studies is the hypothesis that abnormal neurotransmission at 5-HT(2) receptors may be involved in the pathophysiology of schizophrenia. This review highlights recent pharmacological and clinical advances in the understanding of the potential use of serotonin 5-HT(2) receptor antagonists in the treatment of schizophrenia.

Entities:  

Year:  2001        PMID: 16025390

Source DB:  PubMed          Journal:  IDrugs        ISSN: 1369-7056


  17 in total

1.  Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics.

Authors:  Georg Juckel; Florian Schlagenhauf; Michael Koslowski; Dimitri Filonov; Torsten Wüstenberg; Arno Villringer; Brian Knutson; Thorsten Kienast; Jürgen Gallinat; Jana Wrase; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2006-05-24       Impact factor: 4.530

2.  Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.

Authors:  Florian Schlagenhauf; Georg Juckel; Michael Koslowski; Thorsten Kahnt; Brian Knutson; Theresa Dembler; Thorsten Kienast; Jürgen Gallinat; Jana Wrase; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2007-12-21       Impact factor: 4.530

3.  A meta-analysis of peripheral blood nerve growth factor levels in patients with schizophrenia.

Authors:  X-Y Qin; H-T Wu; C Cao; Y P Loh; Y Cheng
Journal:  Mol Psychiatry       Date:  2017-01-10       Impact factor: 15.992

4.  Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.

Authors:  Shahin Akhondzadeh; Raofeh Ghayyoumi; Farzin Rezaei; Bahman Salehi; Amir-Hossein Modabbernia; Azad Maroufi; Gholam-Reza Esfandiari; Mehrangiz Naderi; Fariba Ghebleh; Mina Tabrizi; Shams-Ali Rezazadeh
Journal:  Psychopharmacology (Berl)       Date:  2010-10-15       Impact factor: 4.530

Review 5.  The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.

Authors:  Erin M MacKenzie; John Odontiadis; Jean-Michel Le Mellédo; Trevor I Prior; Glen B I Baker
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

6.  MiR-4763-3p targeting RASD2as a Potential Biomarker and Therapeutic Target for Schizophrenia.

Authors:  Jiao Wang; Wenxin Qi; Hongwei Shi; Lin Huang; Fujiang Ning; Fushuai Wang; Kai Wang; Haotian Bai; Hao Wu; Junyi Zhuang; Huanle Hong; Haicong Zhou; Hu Feng; Yinping Zhou; Naijun Dong; Li Liu; Yanyan Kong; Jiang Xie; Robert Chunhua Zhao
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

7.  A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.

Authors:  Maryam Noroozian; Sina Ghasemi; Seyed-Mohammad-Reza Hosseini; Amirhossein Modabbernia; Mohammad-Reza Khodaie-Ardakani; Omid Mirshafiee; Mehdi Farokhnia; Masih Tajdini; Farzin Rezaei; Bahman Salehi; Mandana Ashrafi; Habibeh Yekehtaz; Mina Tabrizi; Shahin Akhondzadeh
Journal:  Psychopharmacology (Berl)       Date:  2013-03-21       Impact factor: 4.530

8.  The effectiveness of computerized cognitive rehabilitation training program in improving cognitive abilities of schizophrenia clients.

Authors:  Mohammad Reza Mohammadi; Zahra Keshavarzi; Siavash Talepasand
Journal:  Iran J Psychiatry       Date:  2014-10

Review 9.  Can antipsychotics improve social cognition in patients with schizophrenia?

Authors:  Katarzyna Kucharska-Pietura; Ann Mortimer
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

10.  Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial.

Authors:  Shahin Akhondzadeh; Hassan Mohajari; Mohammad Reza Mohammadi; Homayoun Amini
Journal:  BMC Psychiatry       Date:  2003-06-19       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.